- Home
- PLAY vs AUTL Comparison
PLAY vs AUTL Comparison
Compare PLAY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLAY | AUTL |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.5M | 431.2M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PLAY | AUTL |
|---|---|---|
| Price | $12.96 | $1.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $25.29 | $8.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $1.89 | $669.62 |
| Revenue Next Year | $4.69 | $79.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $12.90 | $1.11 |
| 52 Week High | $35.38 | $2.70 |
Technical Indicators
Market Signals| Indicator | PLAY | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 43.23 |
| Support Level | N/A | $1.45 |
| Resistance Level | $15.55 | $1.52 |
| Average True Range (ATR) | 0.83 | 0.11 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 5.39 | 1.06 |
Price Performance
Historical ComparisonAbout PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.